The Newsroom

Find out the latest about Calidi. Announcements, press coverage, publications, and company info‚ÄĒit‚Äôs all here.

Press Release

Calidi Biotherapeutics to Highlight Novel Systemic Enveloped Oncolytic Virotherapy Platform Designed to Target All Tumor Sites at Upcoming Conference

A close up of a cell in the air.
Press Release
event
NeuroNova
Supernova

Calidi Biotherapeutics to Highlight Novel Systemic Enveloped Oncolytic Virotherapy Platform Designed to Target All Tumor Sites at Upcoming Conference

February 12, 2024
Discover More
Discover More
Discover More
Press Release
event
NeuroNova
Supernova

Calidi Biotherapeutics Announces the Appointment of Three New Members to its Scientific and Medical Advisory Board

Calidi Biotherapeutics, Inc. (NYSE American: CLDI or ‚ÄúCalidi‚ÄĚ), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies today announced the appointment of three new members to its Scientific and Medical Advisory Board. These oncology experts are among the country‚Äôs preeminent leaders in cancer biology and clinical care and join the company‚Äôs existing advisors who hail from top cancer research institutions and facilities collaborating with Calidi in the development of its novel immunotherapies targeting high-grade gliomas and solid tumors.

January 8, 2024
Discover More
Discover More
Discover More
Press Release
event
NeuroNova
Supernova

Calidi Biotherapeutics Announces Presentation of Clinical Study for NeuroNova with Recurrent High Grade Glioma at the 8th Oncolytic Virotherapy Summit

Calidi Biotherapeutics, Inc. (NYSE American: CLDI or ‚ÄúCalidi‚ÄĚ), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today announced three presentations on Calidi‚Äôs NeuroNova (NNV) and SuperNova (SNV) allogeneic stem cell-based virotherapy platforms at the upcoming 8th Oncolytic Virotherapy Summit to be held December 12-14, 2023 in Boston, Mass.

December 13, 2023
Discover More
Discover More
Discover More
Press Release
event
NeuroNova
Supernova

Calidi Biotherapeutics Announces Appointment of Pharmaceutical Industry Veteran David LaPré to its Board of Directors

Calidi Biotherapeutics, Inc. (NYSE American: CLDI or ‚ÄúCalidi‚ÄĚ), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today announced the appointment of David LaPr√© to the company‚Äôs Board of Directors effective January 1, 2024

December 12, 2023
Discover More
Discover More
Discover More
Press Release
event
NeuroNova
Supernova

Calidi Biotherapeutics Announces Issuance of New U.S. Patent Covering Novel SuperNova Technology Platform and Updates Anticipated Clinical Milestones

Calidi Biotherapeutics, Inc. (NYSE American: CLDI or ‚ÄúCalidi‚ÄĚ), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today announced the issuance of a new patent for the company‚Äôs SuperNova technology, strengthening its intellectual property portfolio and positioning Calidi to advance its CLD-201 program into the clinic. In addition, the company also provided an update on the timing of its anticipated clinical milestones.

November 20, 2023
Discover More
Discover More
Discover More
Press Release
event
NeuroNova
Supernova

Calidi Biotherapeutics Reports Third Quarter 2023 Operating and Financial Result

Calidi Biotherapeutics, Inc. (NYSE American: CLDI or ‚ÄúCalidi‚ÄĚ), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, reports its financial results for the third quarter 2023 and reviews recent business highlights.

November 14, 2023
Discover More
Discover More
Discover More
Press Release

Calidi Biotherapeutics to Highlight Novel Systemic Enveloped Oncolytic Virotherapy Platform Designed to Target All Tumor Sites at Upcoming Conference

February 12, 2024
Discover More
Press Release

Calidi Biotherapeutics Announces the Appointment of Three New Members to its Scientific and Medical Advisory Board

Calidi Biotherapeutics, Inc. (NYSE American: CLDI or ‚ÄúCalidi‚ÄĚ), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies today announced the appointment of three new members to its Scientific and Medical Advisory Board. These oncology experts are among the country‚Äôs preeminent leaders in cancer biology and clinical care and join the company‚Äôs existing advisors who hail from top cancer research institutions and facilities collaborating with Calidi in the development of its novel immunotherapies targeting high-grade gliomas and solid tumors.

January 8, 2024
Discover More
Press Release

Calidi Biotherapeutics Announces Presentation of Clinical Study for NeuroNova with Recurrent High Grade Glioma at the 8th Oncolytic Virotherapy Summit

Calidi Biotherapeutics, Inc. (NYSE American: CLDI or ‚ÄúCalidi‚ÄĚ), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today announced three presentations on Calidi‚Äôs NeuroNova (NNV) and SuperNova (SNV) allogeneic stem cell-based virotherapy platforms at the upcoming 8th Oncolytic Virotherapy Summit to be held December 12-14, 2023 in Boston, Mass.

December 13, 2023
Discover More
Press Release

Calidi Biotherapeutics Announces Appointment of Pharmaceutical Industry Veteran David LaPré to its Board of Directors

Calidi Biotherapeutics, Inc. (NYSE American: CLDI or ‚ÄúCalidi‚ÄĚ), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today announced the appointment of David LaPr√© to the company‚Äôs Board of Directors effective January 1, 2024

December 12, 2023
Discover More
Press Release

Calidi Biotherapeutics Announces Issuance of New U.S. Patent Covering Novel SuperNova Technology Platform and Updates Anticipated Clinical Milestones

Calidi Biotherapeutics, Inc. (NYSE American: CLDI or ‚ÄúCalidi‚ÄĚ), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, today announced the issuance of a new patent for the company‚Äôs SuperNova technology, strengthening its intellectual property portfolio and positioning Calidi to advance its CLD-201 program into the clinic. In addition, the company also provided an update on the timing of its anticipated clinical milestones.

November 20, 2023
Discover More
Press Release

Calidi Biotherapeutics Reports Third Quarter 2023 Operating and Financial Result

Calidi Biotherapeutics, Inc. (NYSE American: CLDI or ‚ÄúCalidi‚ÄĚ), a clinical-stage biotechnology company developing a new generation of targeted immunotherapies, reports its financial results for the third quarter 2023 and reviews recent business highlights.

November 14, 2023
Discover More
Publication
event
NeuroNova
Supernova

Annual Meeting ‚Äď SITC 2023 ‚Äď Nov 1st to 5th 2023 in San Diego, CA, USA.

SUPERNOVA1 (SNV1), A NOVEL ONCOLYTIC-CELL BASED PLATFORM FOR CANCER THERAPY

November 3, 2023
Discover More
Discover More
Publication
event
NeuroNova
Supernova

Development of Allogeneic Stem Cell-Based Platform for Delivery and Potentiation of Oncolytic Virotherapy

National Center for Biotechnology Information

December 13, 2022
Discover More
Discover More
Publication
event
NeuroNova
Supernova

Neural stem cell delivery of an oncolytic adenovirus in newly diagnosed malignant glioma: a first-in-human, phase 1, dose-escalation trial

Lancet Oncology

August 22, 2021
Discover More
Discover More
Publication
event
NeuroNova
Supernova

Abstract 4473: Evaluation of the potential of oncolytic vaccinia virus delivered by autologous SVF to modulate innate and adaptive immunity in patients with diverse solid and hematological malignancies

American Association for Cancer Research

August 15, 2020
Discover More
Discover More
Publication
event
NeuroNova
Supernova

Abstract 6542: CAL1 vaccinia virus as oncolytic agent and potential use of cell-based platform to enhance its therapeutic effects

American Association for Cancer Research

August 15, 2020
Discover More
Discover More
Publication
event
NeuroNova
Supernova

Enhancement of the therapeutic effects of oncolytic vaccinia virus by using autologous and allogeneic cell-based delivery platforms.

Journal of Clinical Oncology

May 25, 2020
Discover More
Discover More
Media

Executive Interview: Boris Minev, MD (President, Medical and Scientific Affairs)

February 2, 2024
Media

Executive Interview: Andrew Jackson (CFO)

February 2, 2024
Media

Big Biz TV - Allan Camaisa

Pioneering Progress: Calidi Biotherapeutics CEO Allan Camaisa Unveils Latest Breakthroughs in Cancer Cure Research on Big Biz TV

December 4, 2023
Media

Big Biz TV - Stephen Thesing

Pioneering Progress: Calidi Biotherapeutics CBO Stephen Thesing discusses the latest Breakthroughs in Cancer Cure Research on Big Biz TV

December 4, 2023
Media

Good Morning San Diego, Calidi Bio Treatments Discussed

April 13, 2019
Media

KUSI San Diego News - Calidi Bio CEO, Allan Camaisa Interviewed

April 12, 2019
In The News

Calidi Biotherapeutics: A Promising Player in the Cancer Treatment Market

Calidi Biotherapeutics Inc (NYSE: CLDI) is making waves in the biotech industry with its innovative approach to cancer treatment. The company utilizes allogeneic stem cells to deliver oncolytic viruses directly to tumors, offering new hope for patients.

October 9, 2023
Discover More
Discover More
In The News

Analyst Bullish On Calidi Biotherapeutics, Newly Listed Cancer Treatment Player

Baird initiates coverage on Calidi Biotherapeutics Inc CLDI, which uses allogeneic stem cells to deliver oncolytic viruses to tumors for cancer treatment. Just a month back, Calidi Biotherapeutics became the latest biotech to take the special purpose acquisition company route to the public market

October 9, 2023
Discover More
Discover More

All Courses

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros.

A talented, seasoned group of world-class executives, doctors, and scientists producing revolutionary work.

Learn more